Our 2024 impact report is here! Read now
Ibogaine: The Illegal Drug That Cures Addiction by Trevor Clinger
  Send as gift   Add to Wish List

Almost ready!

In order to save audiobooks to your Wish List you must be signed in to your account.

      Log in       Create account
Phone showing make the switch message

Limited-time offer

Get two free audiobooks!

Nowโ€™s a great time to shop indie. When you start a new one credit per month membership supporting local bookstores with promo code SWITCH, weโ€™ll give you two bonus audiobook credits at sign-up.

Sign up today

Ibogaine: The Illegal Drug That Cures Addiction

$1.15

Narrator Al Remington

This audiobook uses AI narration.

Weโ€™re taking steps to make sure AI narration is transparent.

Learn more
Length 8 minutes
Language English
  Send as gift   Add to Wish List

Almost ready!

In order to save audiobooks to your Wish List you must be signed in to your account.

      Log in       Create account

Summary

Ibogaine, a natural compound extracted from a rare vine found in South America, is classified as a Schedule I controlled substance under the U.S. Controlled Substances Act, alongside marijuana and heroin. However, it remains accessible in many countries outside the United States, attracting American tourists seeking its intense, LSD-like effects. As a personal trainer certified by the National Federation of Personal Trainers, I have written this article as part of my ongoing research into substances that affect the body and could potentially contribute to achieving optimal well-being.

Audiobook details

Author:

Narrator:
Al Remington

ISBN:
9798882219269

Length:
8 minutes

Language:
English

Publisher:
Trevor Clinger

Publication date:

Edition:
Unabridged

Phone showing make the switch message

Limited-time offer

Get two free audiobooks!

Nowโ€™s a great time to shop indie. When you start a new one credit per month membership supporting local bookstores with promo code SWITCH, weโ€™ll give you two bonus audiobook credits at sign-up.

Sign up today
Our 2024 impact report is here! Read now